Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jade Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jade Biosciences's position in the market.
The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgAN, is expected to begin first-in-human trials in H2 2025, with interim data expected in H1 2026. Additionally, Jade nominated JADE201 as a development candidate from their JADE-002 program.
Financial results show cash and equivalents of $49.9 million as of March 31, 2025, with an additional $205 million gross proceeds from the April merger. Q1 2025 saw R&D expenses of $20.0 million, G&A expenses of $3.4 million, and a net loss of $38.2 million. The company expects its current cash position to provide runway through 2027.
Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.
The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.
FAQ
What is the current stock price of Jade Biosciences (JBIO)?
What is the market cap of Jade Biosciences (JBIO)?
